EpiAxis Therapeutics was thrilled to present at the Wholesale Investor Venture & Capital Europe Conference on 5-6 July 2023.
Venture & Capital 2023 was an exclusive conference designed to empower high-net-worth VCs, family offices and professional investors with unparalleled access to investment opportunities and exclusive networking.
It featured an exclusive showcase of innovative companies, providing direct access to exclusive investment opportunities. The power-packed agenda was filled with insightful panel sessions, company pitches and inspiring keynote presentations.
EpiAxis Therapeutics CEO Dr Jeremy Chrisp discussed the company’s focus on transforming the lives of cancer patients and meeting the urgent need for more effective treatments. The company recently nominated epiresatide as its lead candidate for IND advancement.
Epiresatide is a generation 2.1 stapled peptide specifically targeting nuclear LSD1, which offers a novel mode of action. Designed to address the challenge of treatment resistance and prevention of cancer recurrence in numerous haematological and solid tumours, epiresatide has demonstrated superior biological performance in modulating LSD1 demethylase activities, coupled with an excellent pre-clinical safety and tolerability profile.
“This is a pivotal valuation inflection point for shareholders and provides momentum for EpiAxis’ fundraising and partnering activities,” Dr Chrisp said.
“Currently, EpiAxis is actively seeking collaborations and investment opportunities to accelerate the development and commercialisation of epiresatide, cementing its position at the forefront of the biotechnology industry.”
For further inquiries, please contact:
Phone: +61 421 012 268
j.chrisp@epiaxistherapeutics.com
Watch Dr Chrisp’s Venture & Capital Europe presentation below: